基蛋生物(603387.SH)擬出資2000萬元參投毅達健康成果貳號基金
格隆匯 12 月 25日丨基蛋生物(603387.SH)公佈，為優化投資結構，提升投資價值，公司擬參與投資設立江蘇高投毅達健康成果創新創業貳號基金合夥企業(有限合夥)(暫定名，以企業登記機關最終核准登記的名稱為準，“合夥企業”或“毅達健康成果貳號基金”)，公司作為有限合夥人計劃出資規模為人民幣2000萬元。
江蘇高投毅達健康成果創新創業貳號基金合夥企業(有限合夥)主要投資於大健康領域，包括但不限於生物醫藥、醫療器械、醫療服務和醫療信息化等細分領域，其餘資金投資於其他與大健康有一定關聯度的高科技領域。合夥企業的投資目標主要投資於大健康領域內的成長期優質企業，兼顧初創期和成熟期企業。
毅達健康成果貳號基金主要投資於大健康領域，包括但不限於生物醫藥、醫療器械、醫療服務和醫療信息化等細分領域，其餘資金投資於其他與大健康有一定關聯度的高科技領域，主要通過對未上市企業進行權益性投資，在條件成熟時，通過公開上市或股權轉讓等方式收回投資並取得全體合夥人相應的投資回報。
毅達健康成果貳號基金符合國家相關政策和醫療市場產業化投資方向，基金管理人毅達資本由江蘇高科技投資集團內部混合所有制改革組建，在行業研究能力、資產管理規模、投資專業化程度等方面穩居行業前列，截至2020年11月，毅達資本管理團隊累計管理資本規模1118億元，累計投資支持了925家創業企業，助推其中197家企業登陸境內外資本市場，投資領域包括健康產業、新材料、先進製造等行業，投資毅達健康成果貳號基金有利於為公司發展開闢新思路，有利於公司充分利用資本市場優勢提高公司自有資金的使用效率，有利於公司尋找大健康領域中具有核心競爭力、具備高成長性或較強增長潛質的優質企業或項目，能夠為公司夯實產業基礎和佈局醫療健康產業前沿、佈局大健康生態圈帶來積極影響，有利於進一步拓展公司的產業佈局，提升公司的盈利能力，為公司後期打造新的利潤增長點，實現公司的持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
